Affiliation:
1. Zhejiang University of Technology
2. Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Abstract
Purpose of review
Currently, glaucoma treatment drugs are facing problems such as low bioavailability, poor patient compliance, discontinuous administration affecting the efficacy of intraocular pressure (IOP) lowering and chronic damage to the eye caused by side effects of drugs. In order to solve these problems and to better meet clinical needs, various new dosage forms have been developed and applied in the clinical setting.
Recent findings
A number of nano formulations and extended-release gels are in successive animal trials, some tear plugs, implants and contact lenses are in clinical trials, and it is believed that more new carrier materials and formulations to improve the bioavailability of drugs are being developed.
Summary
Novel delivery systems for antiglaucoma drugs offer patients more and better therapeutic options, and ongoing or completed studies are providing clear directions for subsequent research to improve clinical applications.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Ophthalmology,General Medicine
Reference43 articles.
1. Advances in molecular pathways r-elated to the pathogenesis of glaucoma;Liu;New Adv Ophthalmol,2021
2. A polymer-based drug delivery system for lowering intraocular pressure;Huang;J Funct Polymers,2021
3. A review on recent drug delivery systems for the posterior segment of the eye;Nayak;Biomed Pharmacother,2018
4. Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis;Yuwaiman;Sci Rep,2016
5. Pulmonary toxicity of benzalkonium chloride;Johnson;J Aerosol Pulmon Drug Deliv,2018